BerGenBio ASA (BGBIO.OL)
BGBIO.OL Stock Price Chart
Explore BerGenBio ASA interactive price chart. Choose custom timeframes to analyze BGBIO.OL price movements and trends.
BGBIO.OL Company Profile
Discover essential business fundamentals and corporate details for BerGenBio ASA (BGBIO.OL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Apr 2017
Employees
13.00
Website
https://www.bergenbio.comCEO
Olav Hellebo BBA, MBA
Description
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
BGBIO.OL Financial Timeline
Browse a chronological timeline of BerGenBio ASA corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 19 May 2026
Upcoming earnings on 19 Feb 2026
Upcoming earnings on 19 Nov 2025
Upcoming earnings on 20 Aug 2025
Earnings released on 21 May 2025
Earnings released on 26 Feb 2025
EPS came in at -kr 0.73 surpassing the estimated -kr 1.09 by +33.03%, while revenue for the quarter reached kr 681.00K.
Earnings released on 13 Nov 2024
EPS came in at -kr 0.63 surpassing the estimated -kr 1.34 by +52.99%.
Earnings released on 21 Aug 2024
EPS came in at -kr 1.39 falling short of the estimated -kr 1.25 by -11.20%.
Stock split effective on 30 May 2024
Shares were split 1:100, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 29 May 2024
EPS came in at -kr 1.00 surpassing the estimated -kr 2.00 by +50.00%, while revenue for the quarter reached kr 167.00K.
Earnings released on 14 Feb 2024
EPS came in at -kr 0.02 falling short of the estimated -kr 0.01 by -100.00%, while revenue for the quarter reached kr 354.00K.
Earnings released on 14 Nov 2023
EPS came in at -kr 0.01 falling short of the estimated -kr 0.01 by -49.93%.
Earnings released on 23 Aug 2023
EPS came in at -kr 0.10 matching the estimated -kr 0.10.
Earnings released on 25 May 2023
EPS came in at -kr 9.26.
Stock split effective on 23 May 2023
Shares were split 2179:250, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 16 Feb 2023
EPS came in at -kr 0.87 falling short of the estimated -kr 0.85 by -2.35%, while revenue for the quarter reached kr 389.00K.
Earnings released on 15 Nov 2022
EPS came in at -kr 0.67 surpassing the estimated -kr 0.82 by +18.29%.
Earnings released on 23 Aug 2022
EPS came in at -kr 0.95 falling short of the estimated -kr 0.83 by -14.46%.
Earnings released on 24 May 2022
EPS came in at -kr 0.92 falling short of the estimated -kr 0.78 by -17.95%.
Earnings released on 16 Feb 2022
EPS came in at -kr 0.78 surpassing the estimated -kr 0.81 by +3.70%, while revenue for the quarter reached kr 774.00K.
Earnings released on 16 Nov 2021
EPS came in at -kr 0.80 surpassing the estimated -kr 1.03 by +22.33%.
Earnings released on 17 Aug 2021
EPS came in at -kr 1.02 falling short of the estimated -kr 0.94 by -8.51%.
Earnings released on 19 May 2021
EPS came in at -kr 0.93 falling short of the estimated -kr 0.80 by -16.25%.
Earnings released on 10 Feb 2021
EPS came in at -kr 0.85 falling short of the estimated -kr 0.78 by -8.97%, while revenue for the quarter reached kr 601.00K.
Earnings released on 17 Nov 2020
EPS came in at -kr 0.77 falling short of the estimated -kr 0.70 by -10.00%.
Earnings released on 18 Aug 2020
EPS came in at -kr 0.86 falling short of the estimated -kr 0.65 by -32.31%.
BGBIO.OL Stock Performance
Access detailed BGBIO.OL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.